{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:59:05Z","timestamp":1783130345392,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ygyno.2021.01.011","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T07:04:31Z","timestamp":1611471871000},"page":"282-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES)"],"prefix":"10.1016","volume":"161","author":[{"given":"Daniel W.","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison F.","family":"Vitonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina N.","family":"Fichorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ygyno.2021.01.011_bb0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2021.01.011_bb0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8","article-title":"Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule","volume":"71","author":"Lloyd","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2021.01.011_bb0015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"Jama."},{"issue":"10022","key":"10.1016\/j.ygyno.2021.01.011_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.ygyno.2021.01.011_bb0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors","volume":"45","author":"Kirchhoff","year":"1991","journal-title":"Biol. Reprod."},{"issue":"6","key":"10.1016\/j.ygyno.2021.01.011_bb0030","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.01.011_bb0045","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2010.08.028","article-title":"Correlates of the preoperative level of CA125 at presentation of ovarian cancer","volume":"119","author":"Cramer","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2014.01.026","article-title":"Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer","volume":"132","author":"Williams","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2021.01.011_bb0060","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2068::AID-CNCR25%3E3.0.CO;2-8","article-title":"Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women","volume":"85","author":"Jeyarajah","year":"1999","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial","volume":"110","author":"Johnson","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.01.011_bb0070","first-page":"489","article-title":"Factors influencing serum CA125II levels in healthy postmenopausal women","volume":"10","author":"Pauler","year":"2001","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3 Pt 1","key":"10.1016\/j.ygyno.2021.01.011_bb0075","first-page":"428","article-title":"CA 125 levels in menopausal women","volume":"76","author":"Westhoff","year":"1990","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.01.011_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.01.011_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.028","article-title":"Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age","volume":"206","author":"Moore","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.01.011_bb0090","series-title":"Vital and Health Statistics Ser 1, Programs and Collection Procedures","first-page":"1","article-title":"National health and nutrition examination survey: plan and operations, 1999\u20132010","volume":"56","author":"Zipf","year":"2013"},{"issue":"1","key":"10.1016\/j.ygyno.2021.01.011_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0591-4","article-title":"Development and validation of circulating CA125 prediction models in postmenopausal women","volume":"12","author":"Sasamoto","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.01.011_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/00401706.1983.10487848","article-title":"Percentage points for a generalized ESD many-outlier procedure","volume":"25","author":"Rosner","year":"1983","journal-title":"Technometrics."},{"key":"10.1016\/j.ygyno.2021.01.011_bb0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cca.2014.08.020","article-title":"Human epididymis protein 4: factors of variation","volume":"438","author":"Ferraro","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/j.ygyno.2021.01.011_bb0110","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-14-0447","article-title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review","volume":"23","author":"Karlsen","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.ygyno.2021.01.011_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"11","key":"10.1016\/j.ygyno.2021.01.011_bb0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2006.06.7884","article-title":"Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer","volume":"25","author":"Hermsen","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.01.011_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-017-0315-6","article-title":"Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort","volume":"10","author":"Fortner","year":"2017","journal-title":"J. Ovarian Res."},{"issue":"11","key":"10.1016\/j.ygyno.2021.01.011_bb0130","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1055-9965.EPI-12-0616","article-title":"Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer","volume":"21","author":"Urban","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"9","key":"10.1016\/j.ygyno.2021.01.011_bb0135","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-08-0150","article-title":"Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer","volume":"17","author":"Lowe","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2021.01.011_bb0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cca.2015.04.028","article-title":"Body mass index does not influence human epididymis protein 4 concentrations in serum","volume":"446","author":"Ferraro","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.ygyno.2021.01.011_bb0145","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1055-9965.EPI-18-1120","article-title":"Predicting Circulating CA125 Levels among Healthy Premenopausal Women","volume":"28","author":"Sasamoto","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000053903","article-title":"Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy","volume":"16","author":"Bon","year":"2001","journal-title":"Fetal Diagn. Ther."},{"issue":"4","key":"10.1016\/j.ygyno.2021.01.011_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/1933719113503416","article-title":"Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition","volume":"21","author":"Orfanelli","year":"2014","journal-title":"Reprod. Sci."},{"issue":"2","key":"10.1016\/j.ygyno.2021.01.011_bb0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2020.09.028","article-title":"Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients","volume":"159","author":"Johnson","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.01.011_bb0165","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1183\/09031936.96.09101989","article-title":"Dose-dependent cigarette smoking-related inflammatory responses in healthy adults","volume":"9","author":"Kuschner","year":"1996","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.ygyno.2021.01.011_bb0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1515\/CCLM.2008.196","article-title":"Plasma interleukin-1beta, \u22126, \u22128 and tumor necrosis factor-alpha as highly informative markers of pelvic inflammatory disease","volume":"46","author":"Lee","year":"2008","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2021.01.011_bb0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/1078-0432.CCR-07-1044","article-title":"Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer","volume":"14","author":"Hefler","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2021.01.011_bb0180","article-title":"Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: meta-analysis of 83 case-control studies involving 35,758 individuals","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ygyno.2021.01.011_bb0185","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2796.1994.tb00856.x","article-title":"Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects","volume":"236","author":"Brattstrom","year":"1994","journal-title":"J. Intern. Med."},{"issue":"42","key":"10.1016\/j.ygyno.2021.01.011_bb0190","doi-asserted-by":"crossref","first-page":"67748","DOI":"10.18632\/oncotarget.11682","article-title":"Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease","volume":"7","author":"Wan","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ygyno.2021.01.011_bb0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2012.11.005","article-title":"The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure","volume":"1","author":"de Boer","year":"2013","journal-title":"JACC Heart Fail."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:00Z","timestamp":1758772680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0090825821000585"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}